Cholic acid is a Small Molecule owned by Travere Therapeutics, and is involved in 3 clinical trials, which were completed.

Cholic acid enhance bile flow and provide the physiologic feedback inhibition of bile acid synthesis. Cholic acid and its conjugates are endogenous ligands of the nuclear receptor, farnesoid X receptor (FXR). FXR regulates enzymes and transporters that are involved in bile acid synthesis and in the enterohepatic circulation to maintain bile acid homeostasis under normal physiologic conditions.

The revenue for Cholic acid is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cholic acid NPV Report.

Cholic acid is currently owned by Travere Therapeutics.

Cholic acid Overview

Cholic acid (Cholbam, Kolbam) is a bile acid preparation. It is formulated as hard gelatin capsules for oral route of administration. Cholbam is indicated for the treatment of pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders). Kolbam is indicated for the treatment of inborn errors in primary bile acid synthesis due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, 2- (or alpha-) methylacyl-CoA racemase (AMACR) deficiency or Cholesterol 7alpha-hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults.

Travere Therapeutics Overview

Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with rare kidney, liver, and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$227.5 million for the fiscal year ended December 2021 (FY2021), an increase of 14.7% over FY2020. The operating loss of the company was US$161.8 million in FY2021, compared to an operating loss of US$176.2 million in FY2020. The net loss of the company was US$180.1 million in FY2021, compared to a net loss of US$169.4 million in FY2020. The company reported revenues of US$53.5 million for the third quarter ended September 2022, a decrease of 1.2% over the previous quarter.

Quick View – Cholic acid

Report Segments
  • Innovator (NME)
Drug Name
  • Cholic acid
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.